BCG remains a widely and frequently used vaccine against TB, with CD4+ T cell responses, including the production of IFN‐γ, IL‐17, and TNF, serving as candidates to evaluate protection following BCG vaccination [13]. This evidence concerns the gene IL17A and tuberculosis.